Shandong Jincheng Pharmaceutical Group Co., Ltd (SHE:300233)
China · Delayed Price · Currency is CNY 14.20
+0.35 (2.53%)
Mar 27, 2026, 3:04 PM CST
SHE:300233 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 2,737 | 3,353 | 3,521 | 3,484 | 3,127 |
Other Revenue | - | 20.18 | 17.66 | 21.46 | 11.78 |
| 2,737 | 3,373 | 3,538 | 3,506 | 3,138 | |
Revenue Growth (YoY) | -18.87% | -4.66% | 0.93% | 11.70% | 5.96% |
Cost of Revenue | 1,751 | 2,070 | 2,073 | 1,932 | 1,542 |
Gross Profit | 986.3 | 1,304 | 1,465 | 1,574 | 1,597 |
Selling, General & Admin | 647.67 | 842.74 | 1,035 | 996.39 | 1,168 |
Research & Development | 188.46 | 170.34 | 184.71 | 171.1 | 178.34 |
Other Operating Expenses | 13.54 | 27.81 | 22.5 | 32.79 | 30.74 |
Operating Expenses | 849.67 | 1,038 | 1,245 | 1,200 | 1,373 |
Operating Income | 136.63 | 265.27 | 219.96 | 373.34 | 223.97 |
Interest Expense | - | -18.48 | -24.92 | -26.82 | -27.04 |
Interest & Investment Income | 2.79 | 12.9 | 15.18 | 15.7 | 24.54 |
Currency Exchange Gain (Loss) | - | 7.58 | 1.34 | 0.97 | -10.1 |
Other Non Operating Income (Expenses) | -8.6 | -2.2 | -3.32 | -2.52 | -4.49 |
EBT Excluding Unusual Items | 130.82 | 265.08 | 208.23 | 360.66 | 206.89 |
Gain (Loss) on Sale of Investments | -0.09 | -1.58 | -0.08 | -12.6 | -1.13 |
Gain (Loss) on Sale of Assets | 2.95 | 3.37 | -1.98 | 1.53 | 1.18 |
Asset Writedown | -55.66 | -16.45 | -2.66 | -21.32 | -39.23 |
Other Unusual Items | - | 18.02 | 21.9 | 17.7 | 28.84 |
Pretax Income | 78.02 | 268.45 | 225.41 | 345.97 | 196.55 |
Income Tax Expense | 35.75 | 60.71 | 32.1 | 60.09 | 73.47 |
Earnings From Continuing Operations | 42.27 | 207.74 | 193.31 | 285.88 | 123.08 |
Minority Interest in Earnings | 1.91 | -10.95 | -18.6 | -12.51 | -15.1 |
Net Income | 44.19 | 196.78 | 174.71 | 273.37 | 107.98 |
Net Income to Common | 44.19 | 196.78 | 174.71 | 273.37 | 107.98 |
Net Income Growth | -77.55% | 12.63% | -36.09% | 153.15% | - |
Shares Outstanding (Basic) | 368 | 378 | 388 | 385 | 386 |
Shares Outstanding (Diluted) | 368 | 378 | 388 | 385 | 386 |
Shares Change (YoY) | -2.70% | -2.53% | 0.84% | -0.17% | -0.60% |
EPS (Basic) | 0.12 | 0.52 | 0.45 | 0.71 | 0.28 |
EPS (Diluted) | 0.12 | 0.52 | 0.45 | 0.71 | 0.28 |
EPS Growth | -76.92% | 15.56% | -36.62% | 153.57% | - |
Free Cash Flow | 218.76 | 153.97 | 321.18 | -118.04 | 61.04 |
Free Cash Flow Per Share | 0.59 | 0.41 | 0.83 | -0.31 | 0.16 |
Dividend Per Share | - | 0.250 | 0.200 | 0.150 | 0.198 |
Dividend Growth | - | 25.00% | 33.33% | -24.31% | -1.82% |
Gross Margin | 36.04% | 38.65% | 41.40% | 44.89% | 50.87% |
Operating Margin | 4.99% | 7.86% | 6.22% | 10.65% | 7.14% |
Profit Margin | 1.61% | 5.83% | 4.94% | 7.80% | 3.44% |
Free Cash Flow Margin | 7.99% | 4.56% | 9.08% | -3.37% | 1.94% |
EBITDA | 455.62 | 582.11 | 525.43 | 624.67 | 443.16 |
EBITDA Margin | 16.65% | 17.26% | 14.85% | 17.82% | 14.12% |
D&A For EBITDA | 318.99 | 316.84 | 305.48 | 251.33 | 219.18 |
EBIT | 136.63 | 265.27 | 219.96 | 373.34 | 223.97 |
EBIT Margin | 4.99% | 7.86% | 6.22% | 10.65% | 7.14% |
Effective Tax Rate | 45.82% | 22.62% | 14.24% | 17.37% | 37.38% |
Revenue as Reported | - | 3,373 | 3,538 | 3,506 | 3,138 |
Advertising Expenses | - | 136.97 | 173.31 | 198.82 | - |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.